Table 3.
Previous AML treatment
| Parameter | Tosedostat 120 mg N=38 |
Tosedostat 240 mg→120 mg N=35 |
Overall N=73 |
|---|---|---|---|
|
| |||
| Remission experience, N (%) | |||
|
| |||
| Refractory (no prior CR) | 18 (47%) | 20 (57%) | 38 (52%) |
| Prior Chemotherapy | 5 (13%) | 7 (20%) | 13 (34%) |
| Prior Hypomethylating Agent | 12 (32%) | 9 (26%) | 20 (77%) |
| Prior Other (inc. LDAC) | 1 (3%) | 4 (11%) | 6 (66%) |
|
| |||
| Prior CR lasting up to 6 months | 6 (16%) | 8 (23%) | 14 (19%) |
|
| |||
| Prior CR lasting between 6 to 12 months | 14 (37%) | 7 (20%) | 21 (29%) |
|
| |||
| Duration of Prior CR (days) | |||
|
| |||
| Median (IQR) a | |||
| Prior Chemotherapy | 210 (157, 253) | 183 (99, 281) | 208 (117, 267) |
| Prior Hypomethylating Agent | 218 (192, 254) | 183 (99, 277) | 215 (192, 267) |
| Prior Other (inc. LDAC) | 151 (103, 162) | 218 (107, 318) | 151 (107, 162) |
|
| |||
| ECOG Performance Status, N (%) | |||
|
| |||
| 0 | 8 (21) | 5 (14) | 13 (18) |
|
| |||
| 1 | 23 (61) | 20 (57) | 43 (59) |
|
| |||
| 2 | 7 (18) | 10 (29) | 17 (23) |
a
Patients with no prior CR were excluded from the calculation of median
IQR = Inter Quartile Range